Recent advances in heparin-induced thrombocytopenia
Research article published in Current opinion in hematology (2011)
Abstract
PURPOSE OF REVIEW: Heparin-induced thrombocytopenia (HIT) is a prothrombotic complication of heparin therapy caused by antibodies against platelet factor 4/heparin complexes. Progress in our understanding of HIT has translated to improvements in treatment and patient outcomes. The objective of this review is to examine recent advances and highlight areas of future inquiry in the epidemiology, diagnosis, and management of this potentially fatal disorder. RECENT FINDINGS: Risk factors for the development of HIT related to heparin administration are well described. Recent identification of host-related risk factors adds to our understanding of disease epidemiology. The limited specificity of clinical diagnosis and widely used immunologic assays for HIT results in frequent overdiagnosis. Novel clinical decision rules and laboratory assays to improve diagnosis are in development. Fondaparinux, bivalirudin, and desirudin have recently been added to the HIT armamentarium. SUMMARY: Despite these advances, critical issues remain to be addressed. Future research efforts will focus on the identification of novel clinical risk factors and biomarkers that will enable recognition of individuals at greatest risk, optimization of diagnostic strategies and use of currently available therapeutics, and development of new drugs that not only reduce thrombotic complications, but also minimize bleeding risk, are well tolerated in patients with organ dysfunction, and facilitate transition to outpatient therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This narrative review summarizes advances in the epidemiology, diagnosis, and management of heparin-induced thrombocytopenia (HIT), a prothrombotic complication driven by antibodies to platelet factor 4/heparin complexes, and notes that fondaparinux, bivalirudin, and desirudin have recently been added to the treatment armamentarium. The ASH relevance is concrete: desirudin is a recombinant derivative of leech hirudin, so this review situates a leech-secretome-derived molecule within real clinical practice as an alternative anticoagulant when heparin cannot be used. As a review it aggregates and interprets prior work rather than generating new data, and it discusses desirudin only as one option among several non-heparin agents, so it should be read as a context-setting summary, not as primary evidence for any specific leech-derived therapy.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026